ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference. The presentation is scheduled for 9:00am ET on January 12, 2022.
Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 9:20am ET.
A webcast of the presentation and question-and-answer session will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005002/en/
INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
[email protected]
OR
FTI Consulting
Robert Stanislaro
212-850-5657
[email protected]
Source: ImmunoGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Versa Networks Recognized in the Gartner® Magic Quadrant™ for Security Service Edge
- Generational Group Advises S&L Computer Services in its Sale to Cyber Advisors
- Boucher LLP Shines Light on Justice: Advocating for Victims of Sexual Assault, Abuse, and More
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!